Lineage Cell Therapeutics (LCTX) Interest & Investment Income (2016 - 2026)
Lineage Cell Therapeutics (LCTX) reported Interest & Investment Income of $405000.0 for Q1 2026, down 15.27% on a YoY basis from $478000.0 in Q1 2025, and up 3.05% quarter-over-quarter from $393000.0 in Q4 2025.
Lineage Cell Therapeutics (LCTX) Interest & Investment Income (2016 - 2026) Analysis & Trends
Lineage Cell Therapeutics has reported Interest & Investment Income for 10 years, with the latest figure at $405000.0 in Q1 2026.
- For the quarter ending Q1 2026, Interest & Investment Income fell 15.27% year-over-year to $405000.0; the trailing twelve-month figure through Mar 2026 stood at $1.6 million (down 6.53% YoY), and the FY2025 full-year result was $1.7 million, down 1.4% from the prior year.
- Interest & Investment Income for Q1 2026 stood at $405000.0, up from $393000.0 in the prior quarter.
- The five-year high for Interest & Investment Income was $478000.0 in Q1 2025, with the low at $366000.0 in Q3 2025.
- Historically, Interest & Investment Income has averaged $418461.5 across 4 years, with a median of $405000.0 in 2026.
- Annual changes were most pronounced in 2024 — Interest & Investment Income increased 21.2% — and 2026, when it retreated 15.27%.
- Lineage Cell Therapeutics' Interest & Investment Income stood at $404000.0 in 2023, then decreased by 2.72% to $393000.0 in 2024, then changed by 0.0% to $393000.0 in 2025, then advanced by 3.05% to $405000.0 in 2026.
- The last three Interest & Investment Income figures came in at $405000.0 (Q1 2026), $393000.0 (Q4 2025), and $366000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 597,319.59 |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 40.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | 305,000.00 |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 103,341.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 114.80 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -14.79 Mn |
| 10 | Lineage Cell Therapeutics | 303.84 Mn | 239.94 Mn | 1.73 Mn | 405,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 405,000.00 |
| Dec 31, 2025 | 393,000.00 |
| Sep 30, 2025 | 366,000.00 |
| Jun 30, 2025 | 454,000.00 |
| Mar 31, 2025 | 478,000.00 |
| Dec 31, 2024 | 393,000.00 |
| Sep 30, 2024 | 397,000.00 |
| Jun 30, 2024 | 463,000.00 |
| Mar 31, 2024 | 462,000.00 |
| Dec 31, 2023 | 404,000.00 |
| Sep 30, 2023 | 433,000.00 |
| Jun 30, 2023 | 382,000.00 |
| Mar 31, 2023 | 410,000.00 |
| Mar 31, 2021 | 2,000.00 |
| Dec 31, 2020 | 2,000.00 |
| Sep 30, 2020 | 252,000.00 |
| Jun 30, 2020 | 380,000.00 |
| Mar 31, 2020 | 405,000.00 |
| Dec 31, 2019 | 407,000.00 |
| Sep 30, 2019 | 399,000.00 |